Search

Your search keyword '"Heffler, Enrico"' showing total 1,158 results

Search Constraints

Start Over You searched for: Author "Heffler, Enrico" Remove constraint Author: "Heffler, Enrico"
1,158 results on '"Heffler, Enrico"'

Search Results

1. Multidisciplinary Decision-Making—ITAlian Consensus After Two Years of Real Practice on the Management of Severe Uncontrolled CRSwNP by Biologics (ITACA Study)

2. Exploring Definitions and Predictors of Response to Biologics for Severe Asthma

5. Profiling severe asthma: Any relevance for age? An analysis from Severe Asthma Network Italy (SANI) cohort

6. International Variation in Severe Exacerbation Rates in Patients With Severe Asthma

7. Impact of pre-biologic impairment on meeting domain-specific biologic responder definitions in patients with severe asthma

8. Analysis of comorbidities and multimorbidity in adult patients in the International Severe Asthma Registry

10. Severe Asthma Network Italy Definition of Clinical Remission in Severe Asthma: A Delphi Consensus

13. Impact of Initiating Biologics in Patients With Severe Asthma on Long-Term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER): Data From the International Severe Asthma Registry

15. Nasal cytology as a reliable non-invasive procedure to phenotype patients with type 2 chronic rhinosinusitis with nasal polyps

18. Effectiveness and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps and associated comorbidities: a multicentric prospective study in real life

19. Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma

20. Interleukin‐5 as a pleiotropic cytokine orchestrating airway type 2 inflammation: Effects on and beyond eosinophils.

21. Defining a Severe Asthma Super-Responder: Findings from a Delphi Process

22. Severe asthma: One disease and multiple definitions

24. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial

27. Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life

28. Baseline Systemic Oral Corticosteroid Use in Patients with Asthma Initiating Dupilumab Treatment in the Real World: From the RAPID Global Registry

29. Real-world biologics response and super-response in the International Severe Asthma Registry cohort

30. Association between pre-biologic T2-biomarker combinations and response to biologics in patients with severe asthma

32. Eosinophils, Eosinophilic Gastrointestinal Diseases, and Inflammatory Bowel Disease: A Critical Review.

33. Baseline Systemic Oral Corticosteroid Use in Patients with Asthma Initiating Dupilumab Treatment in the Real World: From the RAPID Global Registry.

34. Radiological Versus Clinical 1‐Year Outcomes of Dupilumab in Refractory CRSwNP: A Real‐Life Study.

35. Effect of an educational intervention delivered by pharmacists on adherence to treatment, disease control and lung function in patients with asthma

36. Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)

37. Beliefs and preferences regarding biological treatments for severe asthma

38. Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry

39. Acute asthma management during SARS-CoV2-pandemic 2020

40. Characterization of Severe Asthma Worldwide: Data From the International Severe Asthma Registry

41. International Severe Asthma Registry: Mission Statement

42. Reply to “Exploring the long-term effects of biologic initiation in severe asthma: Insights from the International Severe Asthma Registry”

43. Baseline Disease Characteristics Among Patients with Chronic Rhinosinusitis with Nasal Polyps and Coexisting Asthma in the Global AROMA registry

44. Airways Type-2 Related Disorders: Multiorgan, Systemic or Syndemic Disease?

45. Radiological Versus Clinical 1‐Year Outcomes of Dupilumab in Refractory CRSwNP: A Real‐Life Study

46. EUFOREA/EPOS2020 statement on the clinical considerations for CRSwNP care

47. Impact of pre-biologic impairment on meeting domain-specific biologic responder definitions in patients with severe asthma

49. The Severe Asthma Network in Italy: Findings and Perspectives

50. Shadow cost of oral corticosteroids-related adverse events: A pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry

Catalog

Books, media, physical & digital resources